Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiovascular (CV) Risk Clear all
Suspended Not applicable Interventional

Weight Management After Cancer for Survivors in Rural Communities

NCT07426952
View directory record Official record
Conditions
Breast Cancer Survivorship, Weight Management, Cardiovascular (CV) Risk, Breast Cancer
Interventions
WeCan-Rural Program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
3
States / cities
Henderson, North Carolina • Laurinburg, North Carolina • Lumberton, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 10, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NCT02666664
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Jun 10, 2026, 1:51 AM EDT
Recruiting Phase 1 Interventional

Prevention of Progression of Prediabetes, Obesity and CV Risk

NCT06446531
View directory record Official record
Conditions
Pre-Diabetes, Weight, Body, Cardiovascular Diseases
Interventions
Placebo, Rybelsus Tablet, Jardiance 25Mg Tablet, Metformin, Actos
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jun 10, 2026, 1:51 AM EDT
Completed No phase listed Observational

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

NCT07096063
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
Interventions
Tirzepatide, Dulaglutide, Semaglutide, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
887,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jun 10, 2026, 1:51 AM EDT
Completed Not applicable Interventional Results available

Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness

NCT06025721
View directory record Official record
Conditions
Heart Diseases, Diabetes Mellitus, Type 2, Pre-diabetes, Hypertension, Hyperlipidemias
Interventions
Cardiovascular Risk Homeless Support
Behavioral
Lead sponsor
Katherine Vickery
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jun 10, 2026, 1:51 AM EDT
Recruiting Phase 4 Interventional

The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk

NCT05152888
View directory record Official record
Conditions
Stable Coronary Disease
Interventions
Evolocumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jun 10, 2026, 1:51 AM EDT
Completed No phase listed Observational

An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients

NCT00681759
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2008 · Synced Jun 10, 2026, 1:51 AM EDT
Recruiting Phase 3 Interventional

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
15,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
310
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 254 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 10, 2026, 1:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Role of Mobile Apps in Promoting Cardiovascular Health and Motivation to Exercise During Pregnancy

NCT07166822
View directory record Official record
Conditions
Cardiovascular (CV) Risk, Exercise
Interventions
Experimental group using BumptUp mobile exercise app
Behavioral
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jun 10, 2026, 1:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pulses: Optimizing Pulse Consumption for Cardiometabolic Health

NCT06861153
View directory record Official record
Conditions
Cardiovascular (CV) Risk, Healthy Eating Index, HbA1c, Lipid Profile, CRP
Interventions
Pulses 1.5 cups Group, Pulses 3 cups Group, My Plate Group (Control)
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jun 10, 2026, 1:51 AM EDT
Recruiting No phase listed Observational

The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women

NCT07284082
View directory record Official record
Conditions
HIV, Menopause, Cardiovascular (CV) Risk, Carotid Arteriosclerosis, Body Composition
Interventions
Whole body MRI
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 10, 2026, 1:51 AM EDT
Completed Phase 3 Interventional

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

NCT01516541
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions
Background care, Placebo, dalcetrapib
Other · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
45 Years and older
Enrollment
2,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
121
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 112 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 10, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jun 10, 2026, 1:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Incorporating CV Risk Assessment in AYA Visits

NCT05384834
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
#HerHeart tool
Behavioral
Lead sponsor
Emory University
Other
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jun 10, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

NCT01327846
View directory record Official record
Conditions
Atherosclerosis
Interventions
Canakinumab, Placebo, Standard of care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
315
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Jun 10, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

NCT01323153
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
dalcetrapib, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
45 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Pensacola, Florida • Saginaw, Michigan • Saint Cloud, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jun 10, 2026, 1:51 AM EDT
Terminated Not applicable Interventional Results available

Feasibility Study to Improve AF Outcomes Using a Digital Application for CV Risk Reduction

NCT04050982
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
AF CARE, Usual Care
Device · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Jun 10, 2026, 1:51 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women

NCT04014348
View directory record Official record
Conditions
Cardiovascular (CV) Risk
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
19 Years to 45 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 1:51 AM EDT
Not yet recruiting Phase 2 Interventional

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

NCT07223385
View directory record Official record
Conditions
Prostate Cancer (Diagnosis), Prostate Cancer Stage IV, CV Risk
Interventions
Cardio-Oncology Referral, Notification to PCP/General Cardiologist
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
45 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 10, 2026, 1:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise & Diet Effects on CV Risk in Firefighters

NCT03344198
View directory record Official record
Conditions
Cardiovascular Risk Factor, Blood Pressure, Exercise, Diet Modification, Health Promotion
Interventions
Circuit Training exercise & Modified Mediterranean diet
Behavioral
Lead sponsor
University of New Hampshire
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Marcos, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Jun 10, 2026, 1:51 AM EDT